Table 1 Basic characteristics of included studies
From: Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis
| Source | Country/Area | Follow- up, M | Included Atropine Dose, % | Age, Year | Baseline Refraction, Diopter (Mean ± SD) | Experimental group | Control group | Total No. of Patients (test group/control group) |
|---|---|---|---|---|---|---|---|---|
| Chua et al., 2005 [10] | Singapore | 12 | 1 | 6–12 | −3.58 ± 1.17 | 1% Atropine | placebo | 156/190 |
| Hsiao et al., 2005 [11] | Taiwan | 18 | 0.5 | <18 | −3.26 ± 0.15 | 0.5%Atropine+Multi-focal | Multi-focal lenses | 66/61 |
| Kumaran et al., 2015 [12] | Singapore | 36 | 1 | 6–12 | −3.36 | 1% Atropine | placebo | 147/166 |
| Polling et al., 2016 [13] | Europeans | 12 | 0.5 | <18 | −6.6 ± 3.3 | 0.5% Atropine | placebo | 60/17 |
| Shih et al., 2001 [14] | Taiwan | 18 | 0.5 | 6–13 | −3.28 ± 0.13 | 0.5%Atropine+multi-focal | multi-focal glasses | 66/61 |
| Shin et al., 1999 [15] | Taiwan | 12 | 0.5 | 6–13 | −4.89 ± 2.06 | 0.5,0.25,0.1% Atropine | placebo | 41/49 |
| Wang et al., 2017 [16] | China | 12 | 0.5 | 5–10 | −1.3 ± 0.4 | 0.5% Atropine | placebo | 63/63 |
| Yam et al., 2018 [17] | China | 12 | 0.05 | 4–12 | −3.98 ± 1.69 | 0.05,0.025,0.01% Atropine | placebo | 110/111 |
| YEN et al., 1989 [18] | Taiwan | 12 | 1 | 6–14 | −1.523 ± 0.960 | 1% Atropine | placebo | 32/32 |
| Yi et al., 2015 [19] | China | 12 | 1 | 7–12 | −1.23 ± 0.32 | 1% Atropine | placebo | 68/64 |